Karl Rothweiler

Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways. Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl Read our Community Guidelines: https://merus.nl/community-guidelines/

ORCA Therapeutics B.V. is a privately-funded biopharmaceutical company designing and developing new oncolytic immunotherapies for treatment of cancer using Oncolytic Replication Competent Agents (ORCA). At ORCA we are passionate about using viruses to cure cancer patients. Our proprietary technologies allow us to engineer powerful oncolytic adenoviruses that selectively kill cancer cells and induce an antitumor immune response. ORCA’s lead compound ORCA-010 is being developed for treatment naive patients with prostate cancer. For more information, please visit http://www.orca-therapeutics.com

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication. Our solution to endosomal entrapment has the potential to re-open myriad drug development pathways for macromolecule therapeutics lacking efficacy and to explore new targets considered “undruggable” by permeabilizing endo-lysosomal membranes, allowing trapped macromolecules to be released, increasing target engagement without negatively impacting the plasma membrane integrity.

In the course of 2022, InteRNA concluded the first part of its Phase 1a clinical trial with lead candidate INT-1B3 showing a positive safety profile. Unfortunately, due to lack of capital InteRNA was not able to start the second part of this trial for which the necessary regulatory approvals were in place. Despite also the already obtained clearance from the FDA for the Phase 1b/2a trial, the outlook on a combinatory trial with one of the leading PD1 inhibitors in the immune-oncology marketplace and a positive FTO analysis, InteRNA has not been able to attract further funding in the distressed financing climate and was forced to cease operations at the end of Q1-2023. Here we wish to extend our sincere gratitude to the participating patients and their families, as well as our employees, board members, clinical and scientific advisors, investors and partners for their support throughout our journey. It is a pity that INT-1B3 with its promising and unique Mode of Action did not get the chance to be validated in a clinical trial for its efficacy.

Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways. Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl Read our Community Guidelines: https://merus.nl/community-guidelines/

ORCA Therapeutics B.V. is a privately-funded biopharmaceutical company designing and developing new oncolytic immunotherapies for treatment of cancer using Oncolytic Replication Competent Agents (ORCA). At ORCA we are passionate about using viruses to cure cancer patients. Our proprietary technologies allow us to engineer powerful oncolytic adenoviruses that selectively kill cancer cells and induce an antitumor immune response. ORCA’s lead compound ORCA-010 is being developed for treatment naive patients with prostate cancer. For more information, please visit http://www.orca-therapeutics.com

Aglaia is an investment fund fully focused on the fight against cancer and the development of improved anti-cancer drugs in particular. Aglaia has a proven ability to select and mature early-stage breakthrough inventions that have the potential to transform cancer treatment. For more information, please visit www.aglaia-oncology.com